Interest in Genting spurred by progress in Alzheimer's treatment

KUALA LUMPUR: At 9.43am, Genting Bhd's stock was down eight sen or 1.53% to RM5.16 a share, trimming the previous session's steep gains that were underpinned by TauRx Pharmaceuticals Ltd's progress in the development of a drug for Alzheimer's disease.

Genting had seen a surge in investor interest as 20.3%-owned TauRx, a global leader in tau-based research, released optimistic data from the Phase 3 clinical trial of an oral drug for Alzheimer's disease called HMTM.